Phaseline

Companies › Interna Therapeutics

Interna Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Apo-Si-K170A-C76
small interfering RNA (siRNA) against SARS-CoV-2
SARS-COV-2Phase 1SARS-CoV-2 (COVID-19) Infection–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07095049Apo-Si-K170A-C76Phase 1SARS-CoV-2 (COVID-19) InfectionInfectious diseaseJul 2025

Targets

SARS-COV-2 (1)

Companies with the same targets

BioNTech SE Novavax

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.